Listening to patients is a vital part of CADTH’s work. We recognize that patients have unique knowledge about what it is like to live with a specific disease or medical condition. They can describe advantages and disadvantages of current therapies, which may not be reported in published literature. And they can tell us what they would most value from a new treatment.
We also know that there may be other stakeholders — individuals and organizations — with important insights to contribute to our work.
CADTH has taken steps to capture all of this evidence. We do this in two ways:
- Input is solicited at the outset of a project and is usually reserved for patient groups.
- Feedback is requested after an initial recommendation or draft report has been produced. Eligibility to provide feedback varies depending on the CADTH product, but it is often open to anyone with an interest in the work.
You can use the links that follow to explore engagement opportunities that might be relevant to you.
CADTH Common Drug Review Patient Group Input
The CADTH Common Drug Review (CDR) undertakes rigorous, objective reviews of drugs and provides formulary listing recommendations to Canada’s publicly funded health plans (except Quebec).
CADTH Pan-Canadian Oncology Drug Review Patient Group Input and Feedback
The CADTH pan-Canadian Oncology Drug Review (pCODR) undertakes rigorous, objective reviews of cancer drugs and makes funding recommendations to Canada’s provinces and territories (except Quebec).
Other Stakeholder Feedback
CADTH produces a variety of different types of reports related to health technologies, including prescription drugs and medical devices. CADTH frequently invites feedback on this work from interested parties.